UChicago Medicine
C

Reducing Disparities in Lymphoma Care With a Focus on DLBCL

By UChicago Medicine FEATURING Christopher Flowers
By UChicago Medicine FEATURING Christopher Flowers
55 views
July 29, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Related Content

AUTOPLAY
32:36
MyCancerHaven

Experts Discuss the Basics of Diagnosis and Treatment of DLBCL

Feat. R. Vij, A. Cashen
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
16:34
Jennifer Amengual

Top 5 Lymphoma Abstracts From ASH

35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

20:34
UChicago Medicine

Sequencing of Bispecifics With Other Therapies in DLBCL

Feat. E. Budde
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

04:32
Yasmin Karimi

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski